Inactief instrument

Andere talen RegeneRx Biopharmaceuticals, Inc. Other OTC

Aandelen

RGRX

US75886X1081

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations	16-08-23
RegeneRx Receives Stockholder Approval for Reverse Stock Split	07-08-23
RegeneRx Biopharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K	07-08-23
RegeneRx To Extend Consent Solicitation Vote	01-08-23
RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.	03-07-23
RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding	13-06-23
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259	14-04-23
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259	13-04-23
RegeneRx Issues Letter To Stockholders	11-04-23
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operation. (form 10-K)	11-04-23
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	11-04-23
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	11-04-23
Thymosin Beta 4 Research Leads Toward Potential Future Anti-Aging Therapy	31-01-23
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy	31-01-23
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy	03-01-23
Regenerx Biopharmaceuticals, Inc. Reports New Scientific Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy	03-01-23
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14-11-22
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14-11-22
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease	24-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen RegeneRx Biopharmaceuticals, Inc. Other OTC

Aandelen

RGRX

US75886X1081

Andere talen

Filters